Published in J Immunol on April 15, 2006
Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med (2009) 4.27
Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med (2011) 3.85
The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res (2011) 2.60
Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol (2010) 2.44
Type I interferons in infectious disease. Nat Rev Immunol (2015) 2.37
Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med (2011) 2.09
Natural killer cells promote early CD8 T cell responses against cytomegalovirus. PLoS Pathog (2007) 1.93
Innate immune control and regulation of influenza virus infections. J Leukoc Biol (2009) 1.92
Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med (2007) 1.89
Type I interferon response and innate immune sensing of cancer. Trends Immunol (2012) 1.59
Regulation of effector and memory T-cell functions by type I interferon. Immunology (2011) 1.58
Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J Immunol (2009) 1.55
Induction and inhibition of type I interferon responses by distinct components of lymphocytic choriomeningitis virus. J Virol (2010) 1.52
Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy. Cancer Immunol Immunother (2011) 1.47
IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol (2009) 1.43
Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. J Clin Invest (2011) 1.33
Evolutionary genetic dissection of human interferons. J Exp Med (2011) 1.32
Surviving the crash: transitioning from effector to memory CD8+ T cell. Semin Immunol (2009) 1.31
The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming. Immunology (2009) 1.29
A temporal role of type I interferon signaling in CD8+ T cell maturation during acute West Nile virus infection. PLoS Pathog (2011) 1.26
Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood (2010) 1.24
The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog (2013) 1.23
Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood (2009) 1.23
TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway. Blood (2011) 1.21
Innate and adaptive immune responses to herpes simplex virus. Viruses (2009) 1.14
Inhibition of the type I interferon antiviral response during arenavirus infection. Viruses (2010) 1.11
Polyinosinic-polycytidylic acid is the most effective TLR adjuvant for SIV Gag protein-induced T cell responses in nonhuman primates. J Immunol (2013) 1.09
Vesicular stomatitis virus M protein mutant stimulates maturation of Toll-like receptor 7 (TLR7)-positive dendritic cells through TLR-dependent and -independent mechanisms. J Virol (2009) 1.07
Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus. J Virol (2011) 1.02
IFN-α subtypes: distinct biological activities in anti-viral therapy. Br J Pharmacol (2013) 1.02
Activation-induced non-responsiveness (anergy) limits CD8 T cell responses to tumors. Semin Cancer Biol (2007) 1.01
Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther (2012) 1.01
Wiskott-Aldrich syndrome protein-mediated actin dynamics control type-I interferon production in plasmacytoid dendritic cells. J Exp Med (2013) 1.00
Innate immunity to influenza virus: implications for future therapy. Expert Rev Clin Immunol (2008) 0.99
SHP-1 in T cells limits the production of CD8 effector cells without impacting the formation of long-lived central memory cells. J Immunol (2010) 0.99
Effects of adjuvants on IgG subclasses elicited by virus-like particles. J Transl Med (2012) 0.99
Absence of IFN-beta impairs antigen presentation capacity of splenic dendritic cells via down-regulation of heat shock protein 70. J Immunol (2009) 0.99
Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity. Vaccine (2009) 0.96
Rigid interferon-alpha subtype responses of human plasmacytoid dendritic cells. J Interferon Cytokine Res (2008) 0.95
Selective Blockade of Interferon-α and -β Reveals Their Non-Redundant Functions in a Mouse Model of West Nile Virus Infection. PLoS One (2015) 0.95
dsRNA sensors and plasmacytoid dendritic cells in host defense and autoimmunity. Immunol Rev (2011) 0.93
Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway. Clin Transl Immunology (2016) 0.93
Role of interferon regulatory factor 3 in type I interferon responses in rotavirus-infected dendritic cells and fibroblasts. J Virol (2007) 0.92
Type I interferon signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test dengue vaccines. J Virol (2014) 0.91
Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection. MBio (2015) 0.91
Prolonged antigen storage endows merocytic dendritic cells with enhanced capacity to prime anti-tumor responses in tumor-bearing mice. J Immunol (2010) 0.90
Mechanisms behind functional avidity maturation in T cells. Clin Dev Immunol (2012) 0.90
RIG-I- and MDA5-initiated innate immunity linked with adaptive immunity accelerates beta-cell death in fulminant type 1 diabetes. Diabetes (2011) 0.90
Disease-promoting effects of type I interferons in viral, bacterial, and coinfections. J Interferon Cytokine Res (2015) 0.90
Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes. Retrovirology (2011) 0.90
Plasmacytoid dendritic cells and the control of herpesvirus infections. Viruses (2009) 0.89
IFN-α/β receptor signaling promotes regulatory T cell development and function under stress conditions. J Immunol (2015) 0.88
Type I IFN promotes NK cell expansion during viral infection by protecting NK cells against fratricide. J Exp Med (2016) 0.87
Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control. World J Gastroenterol (2015) 0.87
The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases. Gene (2015) 0.87
Viral vector vaccines make memory T cells against malaria. Immunology (2007) 0.86
LTβR signaling in dendritic cells induces a type I IFN response that is required for optimal clonal expansion of CD8+ T cells. Proc Natl Acad Sci U S A (2011) 0.86
The Regulation of Immune Responses by DC Derived Type I IFN. Front Immunol (2013) 0.85
Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types. Front Immunol (2014) 0.85
T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee. Hepatology (2014) 0.85
Type I IFN-dependent T cell activation is mediated by IFN-dependent dendritic cell OX40 ligand expression and is independent of T cell IFNR expression. J Immunol (2011) 0.85
Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. Oncoimmunology (2012) 0.84
Type I interferon signaling contributes to the bias that Toll-like receptor 4 exhibits for signaling mediated by the adaptor protein TRIF. Sci Signal (2014) 0.83
The effect of CpG-ODN on antigen presenting cells of the foal. J Immune Based Ther Vaccines (2007) 0.83
Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant. J Biomed Biotechnol (2010) 0.82
Poly(I:C)/alum mixed adjuvant priming enhances HBV subunit vaccine-induced immunity in mice when combined with recombinant adenoviral-based HBV vaccine boosting. PLoS One (2013) 0.82
Molecular basis for checkpoints in the CD8 T cell response: tolerance versus activation. Semin Immunol (2007) 0.82
Exercise Improves Host Response to Influenza Viral Infection in Obese and Non-Obese Mice through Different Mechanisms. PLoS One (2015) 0.81
A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection. PLoS Negl Trop Dis (2013) 0.81
IL-2 mediates CD4+ T cell help in the breakdown of memory-like CD8+ T cell tolerance under lymphopenic conditions. PLoS One (2010) 0.80
Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines. Virol J (2011) 0.80
Role of interferon regulatory factor 7 in T cell responses during acute lymphocytic choriomeningitis virus infection. J Virol (2012) 0.80
Functional limitations of plasmacytoid dendritic cells limit type I interferon, T cell responses and virus control in early life. PLoS One (2013) 0.79
Kinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons and homologous or heterologous booster immunizations. J Virol (2014) 0.79
Plant Viruses as Nanoparticle-Based Vaccines and Adjuvants. Vaccines (Basel) (2015) 0.79
The role of the innate immune system in destruction of pancreatic beta cells in NOD mice and humans with type I diabetes. J Autoimmun (2016) 0.78
A KALA-modified lipid nanoparticle containing CpG-free plasmid DNA as a potential DNA vaccine carrier for antigen presentation and as an immune-stimulative adjuvant. Nucleic Acids Res (2015) 0.77
Breaking T cell tolerance to beta cell antigens by merocytic dendritic cells. Cell Mol Life Sci (2011) 0.77
Regional astrocyte IFN signaling restricts pathogenesis during neurotropic viral infection. J Clin Invest (2017) 0.77
Type I interferon signaling enhances CD8+ T cell effector function and differentiation during murine gammaherpesvirus 68 infection. J Virol (2014) 0.77
Cellular immune responses in multiple sclerosis patients treated with interferon-beta. Clin Exp Immunol (2013) 0.77
In vivo assessment of NS1-truncated influenza virus with a novel SLSYSINWRH motif as a self-adjuvanting live attenuated vaccine. PLoS One (2015) 0.77
IFN-γ Priming Effects on the Maintenance of Effector Memory CD4(+) T Cells and on Phagocyte Function: Evidences from Infectious Diseases. J Immunol Res (2015) 0.76
RIG-I Signaling Is Critical for Efficient Polyfunctional T Cell Responses during Influenza Virus Infection. PLoS Pathog (2016) 0.76
Association between Interferon Response and Protective Efficacy of NS1-Truncated Mutants as Influenza Vaccine Candidates in Chickens. PLoS One (2016) 0.76
CD70 and IFN-1 selectively induce eomesodermin or T-bet and synergize to promote CD8(+) T-cell responses. Eur J Immunol (2015) 0.75
Type I IFN Signaling Is Dispensable during Secondary Viral Infection. PLoS Pathog (2016) 0.75
Commentary: Acute Hemorrhagic Leukoencephalitis (Weston-Hurst Syndrome) in a Patient with Relapse-Remitting Multiple Sclerosis. Front Immunol (2016) 0.75
A correlation of measles specific antibodies and the number of plasmacytoid dendritic cells is observed after measles vaccination in 9 month old infants. Hum Vaccin Immunother (2015) 0.75
Safety, Tolerability, and Immunogenicity of Interferons. Pharmaceuticals (Basel) (2010) 0.75
IFNalpha activates dormant haematopoietic stem cells in vivo. Nature (2009) 7.17
Initial T cell frequency dictates memory CD8+ T cell lineage commitment. Nat Immunol (2005) 5.83
Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol (2003) 5.36
Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol (2002) 3.91
Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med (2011) 3.85
Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity (2008) 3.67
Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood (2002) 3.19
5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med (2008) 3.13
Toward biosimilar monoclonal antibodies. Nat Biotechnol (2008) 3.09
Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood (2002) 2.59
Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. Mol Cell (2013) 2.55
Virus-induced interferon alpha production by a dendritic cell subset in the absence of feedback signaling in vivo. J Exp Med (2002) 2.47
Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol (2006) 2.38
TRADD protein is an essential component of the RIG-like helicase antiviral pathway. Immunity (2008) 2.37
Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. Cell Metab (2010) 2.33
IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev (2006) 2.29
IL-15 promotes the survival of naive and memory phenotype CD8+ T cells. J Immunol (2003) 2.28
Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem (2005) 2.03
Interleukin-21 inhibits dendritic cell activation and maturation. Blood (2003) 2.00
IL-15 constrains mast cell-dependent antibacterial defenses by suppressing chymase activities. Nat Med (2007) 2.00
Cytosolic RIG-I-like helicases act as negative regulators of sterile inflammation in the CNS. Nat Neurosci (2011) 1.96
Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis. J Exp Med (2002) 1.95
CD8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion. J Immunol (2006) 1.92
La Crosse bunyavirus nonstructural protein NSs serves to suppress the type I interferon system of mammalian hosts. J Virol (2007) 1.90
Rapid turnover of effector-memory CD4(+) T cells in healthy humans. J Exp Med (2004) 1.85
Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood (2006) 1.83
Protective role of beta interferon in host defense against influenza A virus. J Virol (2006) 1.80
Macrophage-expressed IFN-β contributes to apoptotic alveolar epithelial cell injury in severe influenza virus pneumonia. PLoS Pathog (2013) 1.74
Retracted A promiscuous liaison between IL-15 receptor and Axl receptor tyrosine kinase in cell death control. EMBO J (2005) 1.72
IL-17-induced CXCL12 recruits B cells and induces follicle formation in BALT in the absence of differentiated FDCs. J Exp Med (2014) 1.67
Preferential induction of CD4+ T cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1. J Immunol (2006) 1.62
Measurement and modeling of human T cell kinetics. Eur J Immunol (2003) 1.61
Fully functional memory CD8 T cells in the absence of CD4 T cells. J Immunol (2004) 1.59
Local type I IFN receptor signaling protects against virus spread within the central nervous system. J Immunol (2009) 1.57
NK cell activation in visceral leishmaniasis requires TLR9, myeloid DCs, and IL-12, but is independent of plasmacytoid DCs. J Exp Med (2007) 1.57
Syntaxin 11 is required for NK and CD8⁺ T-cell cytotoxicity and neutrophil degranulation. Eur J Immunol (2012) 1.57
B-cell kinetics in humans: rapid turnover of peripheral blood memory cells. Blood (2005) 1.52
Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses. J Virol (2007) 1.50
Characterization of the interferon-producing cell in mice infected with Listeria monocytogenes. PLoS Pathog (2009) 1.50
Qualitative differences between naïve and memory T cells. Immunology (2002) 1.48
Type I interferon as a stimulus for cross-priming. Cytokine Growth Factor Rev (2008) 1.48
Type I IFN-mediated protection of macrophages and dendritic cells secures control of murine coronavirus infection. J Immunol (2009) 1.45
Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J (2009) 1.44
Interleukin-21: a new modulator of immunity, infection, and cancer. Cytokine Growth Factor Rev (2007) 1.40
TLR3-induced activation of mast cells modulates CD8+ T-cell recruitment. Blood (2005) 1.39
Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors. Proc Natl Acad Sci U S A (2012) 1.39
Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells. Immunity (2009) 1.38
Ceramide mediates caspase-independent programmed cell death. FASEB J (2005) 1.36
In vivo T lymphocyte dynamics in humans and the impact of human T-lymphotropic virus 1 infection. Proc Natl Acad Sci U S A (2007) 1.36
In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology (2007) 1.35
IL-2 induces in vivo suppression by CD4(+)CD25(+)Foxp3(+) regulatory T cells. Eur J Immunol (2008) 1.34
Direct measurement of T cell subset kinetics in vivo in elderly men and women. J Immunol (2004) 1.34
In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc Natl Acad Sci U S A (2008) 1.34
Tissue macrophages suppress viral replication and prevent severe immunopathology in an interferon-I-dependent manner in mice. Hepatology (2010) 1.33
Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma. J Immunol (2005) 1.33
Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am J Pathol (2009) 1.30
Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components. J Virol (2008) 1.26
Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-alpha/beta. Immunol Cell Biol (2004) 1.21
Common gamma-chain-dependent signals confer selective survival of eosinophils in the murine small intestine. J Immunol (2009) 1.21
Interferon-β and interferon-λ signaling is not affected by interferon-induced refractoriness to interferon-α in vivo. Hepatology (2011) 1.20
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood (2013) 1.20
Retracted Reverse signaling through membrane-bound interleukin-15. J Biol Chem (2004) 1.17
Dendritic cell-derived IL-15 controls the induction of CD8 T cell immune responses. Eur J Immunol (2003) 1.16
Retracted Extracellular ATP induces cytokine expression and apoptosis through P2X7 receptor in murine mast cells. J Immunol (2005) 1.16
Retracted Signaling through P2X7 receptor in human T cells involves p56lck, MAP kinases, and transcription factors AP-1 and NF-kappa B. J Biol Chem (2002) 1.15
Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells. J Immunol (2007) 1.14
Alterations in receptor binding properties of recent human influenza H3N2 viruses are associated with reduced natural killer cell lysis of infected cells. J Virol (2007) 1.14
Effects of type I interferons on Friend retrovirus infection. J Virol (2006) 1.14
TGN1412--a regulator's perspective. Nat Biotechnol (2006) 1.13
Blocking IL-15 prevents the induction of allergen-specific T cells and allergic inflammation in vivo. J Immunol (2005) 1.13
Differential responses of immune cells to type I interferon contribute to host resistance to viral infection. Cell Host Microbe (2012) 1.12
Synergistic and differential modulation of immune responses by Hsp60 and lipopolysaccharide. J Biol Chem (2006) 1.12
TLR signaling in mast cells: common and unique features. Front Immunol (2012) 1.12
How a cytokine is chaperoned through the secretory pathway by complexing with its own receptor: lessons from interleukin-15 (IL-15)/IL-15 receptor alpha. Mol Cell Biol (2008) 1.11
Mast cell-mediated antigen presentation regulates CD8+ T cell effector functions. Immunity (2009) 1.10
Retracted Soluble Interleukin IL-15Ralpha is generated by alternative splicing or proteolytic cleavage and forms functional complexes with IL-15. J Biol Chem (2007) 1.10
Interleukin-21 inhibits dendritic cell-mediated T cell activation and induction of contact hypersensitivity in vivo. J Invest Dermatol (2003) 1.10
Retracted Soluble Axl is generated by ADAM10-dependent cleavage and associates with Gas6 in mouse serum. Mol Cell Biol (2005) 1.10
Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug Discov Today (2007) 1.09
Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies. PLoS One (2008) 1.09
Differential regulation of mast cell degranulation versus cytokine secretion by the actin regulatory proteins Coronin1a and Coronin1b. J Exp Med (2011) 1.07
Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity. PLoS Pathog (2013) 1.07
Antiviral immune responses in gene-targeted mice expressing the immunoglobulin heavy chain of virus-neutralizing antibodies. Proc Natl Acad Sci U S A (2003) 1.06
Glycation of a food allergen by the Maillard reaction enhances its T-cell immunogenicity: role of macrophage scavenger receptor class A type I and II. J Allergy Clin Immunol (2009) 1.05
CD28 superagonists: what makes the difference in humans? Immunity (2008) 1.05
Dendritic cells require STAT-1 phosphorylated at its transactivating domain for the induction of peptide-specific CTL. J Immunol (2009) 1.05
Double-stranded RNA-binding protein E3 controls translation of viral intermediate RNA, marking an essential step in the life cycle of modified vaccinia virus Ankara. J Gen Virol (2006) 1.03
Novel functions of tyrosine kinase 2 in the antiviral defense against murine cytomegalovirus. J Immunol (2005) 1.03
Rapid turnover of T cells in acute infectious mononucleosis. Eur J Immunol (2003) 1.03
Tissue-level regulation of Th1 and Th2 primary and memory CD4 T cells in response to Listeria infection. J Immunol (2002) 1.03
Survival and migration of human dendritic cells are regulated by an IFN-alpha-inducible Axl/Gas6 pathway. J Immunol (2009) 1.03
Influenza B virus ribonucleoprotein is a potent activator of the antiviral kinase PKR. PLoS Pathog (2009) 1.03